- Clever Leaves Portugal sends BRC (Biopharmaceutical Research Company) the first 30 kg. Cannabis Flower with high THC content.
New York, Oct. 06, 2021 (GLOBE NEWSWIRE) – Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW) (“Clever Leaves” or the “Company”), a leading multinational operator and licensed producer of pharmaceutical grade cannabinoids, today announced the export of 30 kg of high-THC cannabis flower from its facilities in Portugal to Biopharmaceutical Research Company (“BRC”), a DEA-licensed pharmaceutical company that develops active pharmaceutical ingredients (API) based on plant and complies with United States federal standards. This fact not only strengthens the entry of Clever Leaves to the United States and consolidates BRC’s ability to conduct international operations, but also positions the two organizations among the first companies to commercialize dried flower cannabis from Portugal to the United States.
Under the agreement, Clever Leaves’ product, which meets strict pharmaceutical standards, will be used for BRC’s pharmaceutical development projects. In addition to this shipment of dried cannabis flower, BRC and Clever Leaves have achieved a solid alliance during the last year through their collaboration in the Project. Change Lives, an initiative announced earlier this year that seeks to contribute up to $ 25 million in medicinal cannabis products to help advance scientific research in the United States.
“This export not only represents an important opportunity for Clever Leaves but also demonstrates the company’s capabilities to find the regulatory path, in compliance with the current regulatory framework, to enter the US, the largest cannabis market in the world”, said Kyle Detwiler, CEO of Clever Leaves.
He added that exporting high-THC dried flower to a company like BRC, licensed by the DEA, “demonstrates our ability to meet stringent regulatory requirements in the US.” Likewise, Kyle Detwiler assured that “it is an honor to provide BRC with the high quality product they need to advance their research, development and production, as well as to become one of the first companies to commercially export dry flower with a high content of THC to the US This shows that we are paving the way for Clever Leaves in the US medical cannabis industry through a partner like BRC. “
“Our partnership with Clever Leaves will continue to open up exciting research opportunities that will one day make a difference in the lives of patients,” said George Hodgin, CEO of Biopharmaceutical Research Company. “We both share the same criteria when it comes to DEA compliance – we take it seriously – so we believe this alliance is just beginning. We are delighted to be partners with Clever Leaves once again and look forward to it. for starting to work with this premium product. “
The Clever Leaves growing facilities in Portugal are located on an area of approximately 836,127 square meters and have high-tech greenhouse facilities of about 10,219 square meters, the expansion of which to about 25,000 square meters is almost complete. . The facility received a license from INFARMED IP, the Portuguese regulatory authority that oversees the pharmaceutical industry in Portugal, to import, export and grow cannabis. Clever Leaves’ sophisticated facilities in Portugal, which are certified by Good Agricultural and Harvesting Practices (GACP), are currently operational and commercially active, with successful exports to several countries, including Australia.
Acerca de Clever Leaves Holdings Inc.
Clever Leaves is a multinational cannabis company with an emphasis on large-scale organic farming and pharmaceutical grade processing as cornerstones of its global cannabis business. With operations and investments in the United States, Canada, Colombia, Germany and Portugal, Clever Leaves has built an effective distribution network and a global presence, with a foundation built on capital efficiency and rapid growth. Clever Leaves aims to be one of the leading cannabis companies in the world, recognized for its principles, people and performance, while fostering a healthier global community. Clever Leaves has received multiple international certifications that have allowed it to increase its export and sales capacity of its operations in Colombia, including the European Union Good Manufacturing Practices Certification (EU GMP), Good Manufacturing Practices Certification (GMP) of the National Institute of Food and Drug Surveillance of Colombia – INVIMA, and Certification of Good Agricultural and Collection Practices (GACP). Clever Leaves received a license in Portugal from Infarmed, the Portuguese health authority, which allows Clever Leaves to grow, import and export dried flowers for medicinal and research purposes. Additionally, the Portuguese operation also received certification in accordance with the GACP and the IMC-GAP. For more information visit https://cleverleaves.com/en/home/.
Acerca de Biopharmaceutical Research Company
Biopharmaceutical Research Company (“BRC”), is a DEA-licensed pharmaceutical company that develops active pharmaceutical ingredients (APIs) for herbal therapies, in compliance with United States federal regulations.
Press contact:
Diana Sigüenza
Strategic Communications Director
+57310-236-8830
Diana.siguenza@cleverleaves.com
Investor inquiry:
Cody Battle
Gateway Investor Relations
+1949-574-3860
CLVR@gatewayir.com
Commercial contact:
Andrew Miller
Vice President Sales – EMEA, North America, and Asia-Pacific
+1416-817-1336
andrew.miller@cleverleaves.com
BRC press contact:
Charlie Patterson
Squared Communications
(202) 680-8132
charlie@sqcomms.com
